---
title: "Xolair (omalizumab) in allergic asthma: Dosing and administration questions"
description: "Dosing and administration questions on Xolair (omalizumab) in allergic asthma, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Dosing, Treatment duration, Administration, and Taking treatment. Questions: What is the Xolair dosage for allergic asthma? Which IgE levels and weights does the Xolair asthma dosing table cover? Can IgE be retested to adjust the Xolair dose? Does the Xolair dose change with weight gain or loss? 3 further questions follow. 7 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/xolair--allergic-asthma/dosing-and-administration"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Xolair (omalizumab) in allergic asthma: Dosing and administration questions

Manufacturer: Genentech, Inc.; Novartis Pharmaceuticals Corporation  
Prescribing information: [Xolair](https://www.gene.com/download/pdf/xolair_prescribing.pdf)

Dosing and administration questions that apply to every indication of Xolair are on [Xolair (omalizumab), all indications: Dosing and administration](https://www.evicenter.com/medical-information/xolair/dosing-and-administration).

## Dosing

<a id="xolair-dosage"></a>

### What is the Xolair dosage for allergic asthma?

> “Administer XOLAIR 75 mg to 375 mg by subcutaneous injection every 2 or 4 weeks.”

Source: [XOLAIR: Dosing Information | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/dosing-and-administration/dosing.html#:~:text=Administer%20XOLAIR%2075%20mg%20to,every%202%20or%204%20weeks.)

> “The recommended dosage is based on serum total IgE level (IU/mL), measured before the start of treatment, and by body weight.”

Source: [XOLAIR: Dosing Information | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/dosing-and-administration/dosing.html#:~:text=The%20recommended%20dosage%20is%20based,treatment%2C%20and%20by%20body%20weight.)

> “Adult and adolescent patients 12 years of age and older: Initiate dosing according to 
> Table 1. 
> • Pediatric patients 6 to <12 years of age: Initiate dosing according to Table 2.”

Source: [XOLAIR: Prescribing information, page 4, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=4)

Note: Tables 1 and 2 of the Prescribing Information give the dose and frequency for each combination of pretreatment serum total IgE level and body weight; the dosing page links them.

<a id="xolair-dosing-table-limits"></a>

### Which IgE levels and weights does the Xolair asthma dosing table cover?

> “For patients aged 6 to <12 years whose pretreatment serum total IgE level or body weight is outside the limits of the dosing table (<30 or >1300 IU/mL and <20 or >150 kg, respectively), there are insufficient data to recommend a dose.”

Source: [XOLAIR: Dosing Information | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/dosing-and-administration/dosing.html#:~:text=For%20patients%20aged%206%20to,data%20to%20recommend%20a%20dose.)

> “For patients aged ≥12 years whose pretreatment serum total IgE level or body weight is outside the limits of the dosing table (<30 or >700 IU/mL and <30 or >150 kg, respectively), there are insufficient data to recommend a dose.”

Source: [XOLAIR: Dosing Information | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/dosing-and-administration/dosing.html#:~:text=For%20patients%20aged%20%E2%89%A512%20years,data%20to%20recommend%20a%20dose.)

<a id="xolair-ige-retesting"></a>

### Can IgE be retested to adjust the Xolair dose?

> “Total IgE levels are elevated during treatment and remain elevated for up to 1 year after the discontinuation of treatment. Retesting of IgE levels during XOLAIR treatment cannot be used as a guide for dose determination.”

Source: [XOLAIR: Dosing Information | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/dosing-and-administration/dosing.html#:~:text=Total%20IgE%20levels%20are%20elevated,a%20guide%20for%20dose%20determination.)

> “Dose determination after treatment interruptions lasting less than 1 year should be based on serum IgE levels obtained at the initial dose determination. Total serum IgE levels may be retested for dose determination if treatment with XOLAIR has been interrupted for 1 year or more.”

Source: [XOLAIR: Dosing Information | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/dosing-and-administration/dosing.html#:~:text=Dose%20determination%20after%20treatment%20interruptions,for%201%20year%20or%20more.)

<a id="xolair-weight-change"></a>

### Does the Xolair dose change with weight gain or loss?

> “Doses should be adjusted for significant changes in body weight according to the dosing tables.”

Source: [XOLAIR: Dosing Information | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/dosing-and-administration/dosing.html#:~:text=Doses%20should%20be%20adjusted%20for,according%20to%20the%20dosing%20tables.)

## Treatment duration

<a id="xolair-treatment-duration"></a>

### How long should patients stay on Xolair for asthma?

> “Duration of Therapy 
> Periodically reassess the need for continued therapy based upon the patient’s disease severity 
> and level of asthma control.”

Source: [XOLAIR: Prescribing information, page 6, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=6)

## Administration

<a id="xolair-self-injection"></a>

### Can patients self-inject Xolair for asthma?

> “Initiate therapy in a healthcare setting and once therapy has been safely established, the 
> healthcare provider may determine whether self-administration of XOLAIR prefilled 
> syringe or autoinjector by the patient or caregiver is appropriate, based on careful 
> assessment of risk for anaphylaxis and mitigation strategies.”

Source: [XOLAIR: Prescribing information, page 9, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=9)

> “Healthcare providers should consider known risk factors for anaphylaxis to XOLAIR [see 
> Warnings and Precautions (5.1)] and mitigation strategies when selecting patients for self-
> administration. Patient-specific factors including the following criteria should be considered:  
>
> 1a) Asthma, CRSwNP and CSU: Patient should have no prior history of anaphylaxis to 
> XOLAIR or other agents, such as foods, drugs, biologics, etc.”

Source: [XOLAIR: Prescribing information, page 9, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=9)

> “2)   Patient should receive at least 3 doses of XOLAIR under the guidance of a 
> healthcare provider with no hypersensitivity reactions 
> 3)   Patient or caregiver is able to recognize symptoms of anaphylaxis 
> 4)   Patient or caregiver is able to treat anaphylaxis appropriately  
> 5)   Patient or caregiver is able to perform subcutaneous injections with XOLAIR 
> prefilled syringe or autoinjector with proper technique according to the prescribed 
> dosing regimen and Instructions for Use”

Source: [XOLAIR: Prescribing information, page 9, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=9)

Note: Criterion 1a of the Prescribing Information applies to asthma. The administration page of the Xolair HCP site lists the criteria with the food-allergy wording "(except foods)"; the label is quoted here.

## Taking treatment

<a id="xolair-onset-of-effect"></a>

### Does Xolair improve asthma symptoms right away?

> “Inform patients that they may 
> not see immediate improvement in their asthma, CRSwNP, CSU or IgE-mediated food 
> allergy symptoms after beginning XOLAIR therapy.”

Source: [XOLAIR: Prescribing information, page 43, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=43)

## Related pages
- [Medical information: Xolair (omalizumab): Allergic asthma](https://www.evicenter.com/medical-information/xolair--allergic-asthma)
- [Indication](https://www.evicenter.com/medical-information/xolair--allergic-asthma/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/xolair--allergic-asthma/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/xolair--allergic-asthma/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/xolair--allergic-asthma/safety)
- [Specific populations](https://www.evicenter.com/medical-information/xolair--allergic-asthma/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/xolair--allergic-asthma/drug-interactions)
- [Access and coverage](https://www.evicenter.com/medical-information/xolair--allergic-asthma/access-and-coverage)
